Skip to main content

Advertisement

SpringerLink
Log in

Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Tumor–node–metastasis (TNM) stage I colorectal cancer is commonly characterized by a good prognosis, with 5-year survival around 80–90%; nonetheless, it undergoes disease progression in a percentage of cases, although the causes of adverse clinical course still remain to be elucidated. In the present study, we analyzed and compared the immunohistochemical expression of the pro-angiogenic vascular endothelial growth factor (VEGF) as well as the microvessel density (MVD) in a series of 27 surgically resected colorectal carcinomas obtained from patients deceased because of disease progression and in a cohort of 25 colorectal cancers from patients still alive with no evidence of disease progression 5 years after the initial diagnosis. The prognostic value of VEGF expression and of MVD on the overall survival to colorectal cancer was investigated. A variable VEGF immunoexpression was demonstrated in all the analyzed cases. High VEGF expression was significantly more frequent among patients deceased of the disease. These patients also displayed significantly higher MVD counts in their cancer in comparison to the patients alive after 5 years from surgery. Moreover, both high VEGF expression and MVD appeared as significant negative prognostic markers related to a shorter overall survival to stage I colorectal carcinoma, with VEGF representing an independent variable at multivariate analysis. VEGF assessment might be used in order to select those patients with a higher progression risk and to submit them to adjuvant therapies useful to prevent adverse outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S (1999) Cancer statistics. Cancer J Clin 49:8–31

    Article  CAS  Google Scholar 

  2. Wiggers T, Arends JW, Schutter B et al (1988) A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61:386–389

    Article  CAS  PubMed  Google Scholar 

  3. Wu XC, Chen VW, Steele B et al (2001) Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group. Cancer 92:2547–2554

    Article  Google Scholar 

  4. Di Gregorio C, Fante R, Roncucci L et al (1996) Clinical features, frequency and prognosis of Dukes’ A colorectal carcinoma: a population-based investigation. Eur J Cancer 32A:1957–1962

    Article  PubMed  Google Scholar 

  5. Di Gregorio C, Benfatti P, Losi L et al (2005) Incidence and survival of patients with Dukes’A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. Int J Colorectal Dis 20:147–154

    Article  PubMed  Google Scholar 

  6. Wichmann MW, Muller C, Hornung HM (2002) The Colorectal Cancer study Group. Results of long-term follow-up after curative resection of Dukes’ A colorectal cancer. World J Surg 26:732–736

    Article  PubMed  Google Scholar 

  7. Folkman J (1990) What is the evidence that tumour are angiogenesis dependent? J Natl Cancer Inst 82:4–6

    Article  CAS  PubMed  Google Scholar 

  8. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934

    CAS  PubMed  Google Scholar 

  9. Folkman J (1995) Clinical applications of angiogenesis research. N Engl J Med 333:1757–1763

    Article  CAS  PubMed  Google Scholar 

  10. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 86:353–364

    Article  CAS  PubMed  Google Scholar 

  11. Ferrara N, Davis-Smith T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25

    Article  CAS  PubMed  Google Scholar 

  12. Fan F, Wey JS, McCarty MF et al (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24:2647–2653

    Article  CAS  PubMed  Google Scholar 

  13. Cheifetz S, Bellon T, Cales C et al (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267:19027–19030

    CAS  PubMed  Google Scholar 

  14. Burrows FJ, Derbyshire EJ, Tazzari PL et al (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumours: implications for diagnosis and therapy. Clin Cancer Res 1:1623–1634

    CAS  PubMed  Google Scholar 

  15. Miller DW, Graulich W, Karges B (1999) Elevated expression of endoglin, a component of the TGF-β receptor complex, correlates with proliferation of tumour endothelial cells. Int J Cancer 81:568–572

    Article  CAS  PubMed  Google Scholar 

  16. Minhajat R, Mori D, Yamasaki F (2006) Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. Virchows Arch 448:127–134

    Article  CAS  PubMed  Google Scholar 

  17. Saad RS, Liu YL, Nathan G et al (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17:197–203

    Article  CAS  PubMed  Google Scholar 

  18. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumors. International Union Against Cancer (UICC), 6th edn. Wiley-Liss, New York

    Google Scholar 

  19. Ponz de Leon M, Sassatelli R, Sacchetti C (1989) Familial aggregation of tumors in the three-year experience of a population-based colorectal cancer registry. Cancer Res 49:4344–4348

    CAS  PubMed  Google Scholar 

  20. Ponz de Leon M, Benatti P, Percesepe A (1999) Epidemiology of cancer of the large bowel—the 12-year experience of a specialized registry in northern Italy. Ital J Gastroenterol Hepatol 31:10–18

    CAS  PubMed  Google Scholar 

  21. Barresi V, Vitarelli E, Cerasoli S (2009) Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density. Virchows Arch 454:563–571

    Article  CAS  PubMed  Google Scholar 

  22. Barresi V, Tuccari G (2010) Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology. doi:10.1111/j.1440-1789.2010.01105.x

  23. Barresi V, Cerasoli S, Vitarelli E et al (2007) Density of microvessel positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 114:147–156

    Article  CAS  PubMed  Google Scholar 

  24. Barresi V, Cerasoli S, Tuccari G (2008) Correlative evidence that tumour cell-derived caveolin-1 mediates angiogenesis in meningiomas. Neuropathology 28:472–478

    Article  PubMed  Google Scholar 

  25. Torsney E, Charlton R, Parums D et al (2002) Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51:464–470

    Article  CAS  PubMed  Google Scholar 

  26. Fonsatti E, Del Vecchio L, Altomonte M (2001) Endoglin: an accessory component of the TGF-β-binding receptor complex with diagnostic, prognostic, and bio-immunotherapeutic potential in human malignancies. J Cell Physiol 188:1–7

    Article  CAS  PubMed  Google Scholar 

  27. Takahashi Y, Kitadai Y, Bucana CD et al (1995) Expression of vascular endothelial growth factor and its receptors, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 55:3964–3968

    CAS  PubMed  Google Scholar 

  28. Takahashi N, Haba A, Matsuno F et al (2001) Antiangiogenic therapy of established tumours in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61:7846–7854

    CAS  PubMed  Google Scholar 

  29. Kang SM, Maeda K, Onoda N (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumour vascularity and liver metastasis. Int J Cancer 74:502–507

    Article  CAS  PubMed  Google Scholar 

  30. Dassoulas K, Gazouli M, Theodoropoulos G (2010) Vascular endothelial growth factor and endoglin expression in colorectal cancer. J Cancer Res Clin Oncol 136:703–708

    Google Scholar 

  31. Ishigami SI, Arii S, Furutani M et al (1998) Predictive value of vascular endothelial growth factor (VEGF) for metastasis and prognosis of human colorectal cancer. Br J Cancer 78:1379–1384

    CAS  PubMed  Google Scholar 

  32. Weidner N, Semple JP, Welch WR (1991) Tumour angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324:1–8

    CAS  PubMed  Google Scholar 

  33. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779–1802

    Article  CAS  PubMed  Google Scholar 

  34. Bose D, Meric-Bernstam F, Hofstetter W et al (2010) Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 11:373–382

    Google Scholar 

  35. WangY FD, Vanderlaan M et al (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335–345

    Article  Google Scholar 

  36. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685–693

    Article  CAS  PubMed  Google Scholar 

  37. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671–680

    CAS  PubMed  Google Scholar 

  38. Uneda S, Toi H, Tsujie T et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumours by targeting tumour vasculature. Int J Cancer 125:1446–1453

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Human Pathology, University of Messina, Messina, Italy

    Valeria Barresi, Gaetano Barresi & Enrica Vitarelli

  2. Unit of Anatomic Pathology, Hospital of Carpi, Carpi, Italy

    Carmela Di Gregorio

  3. Department of Medicine and Medical Specialities, University of Modena and Reggio-Emilia, Modena, Italy

    Luca Regiani-Bonetti & Maurizio Ponz-De Leon

  4. Dipartimento di Patologia Umana, Policlinico Universitario G. Martino, Pad D, Via Consolare Valeria, 98125, Messina, Italy

    Valeria Barresi

Authors
  1. Valeria Barresi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmela Di Gregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Regiani-Bonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Ponz-De Leon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gaetano Barresi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enrica Vitarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valeria Barresi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barresi, V., Di Gregorio, C., Regiani-Bonetti, L. et al. Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome. Virchows Arch 457, 11–19 (2010). https://doi.org/10.1007/s00428-010-0933-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-010-0933-5

Keywords

Search

Navigation